NFKB1 and rheumatoid arthritis: This nanoparticle system is noncytotoxic, is nonimmunogenic, and has been shown to effectively deliver encapsulated disease-modifying anti-rheumatic drugs (DMARDs) and surface-coated NF-κB decoy ODNs when applied to in vitro models of RA and cystic fibrosis (CF), respectively [24, 25].